Magazyn 2026/2 (11) – Lekarz

2026/09/08

26 min

1 Prof. dr hab. n. med. Anna Zalewska-Janowska, Poza schematem, czyli różne oblicza atopowego zapalenia skóry
2 Dr hab. n. med. Emilia Majsiak, W sieci zależności – AZS, alergia, molekuły
3 Dr n. med. Aleksandra Wieczorek-Kawka, Jak dbać o skórę atopową? Zasady pielęgnacji i błędy
4 Dr n. med. Katarzyna Poznańska-Kurowska, Jak skutecznie leczyć AZS? Przegląd dostępnych terapii
5 Prof. dr. hab. n. med. Marta Chełmińska, Owady jadalne – jeść czy nie jeść? Oto jest pytanie!
6 Lek. Agnieszka Szczukocka, dr hab. n. med. Katarzyna Grzela
7 Diet. Marcelina Bartuzi-Lepczyńska, SIBO czy alergia pokarmowa? Podobne objawy, różne przyczyny
8 Dr n. med. Kamil Janeczek, Poranny katar i kaszel u dziecka. Czy to alergia na roztocze?
9 Dr Barbara Bukowska, Niewidzialni współlokatorzy. Jak wygrać wojnę z roztoczami w sypialni?
10 Aleksandra Lipiec, Ten grzyb jest niemal wszędzie. Cladosporium pod lupą
11 Lek. Danuta Ostrowska-Reguła, Nie daj się zaskoczyć pyłkom. Kiedy zacząć brać leki na alergię?
12 Prof. dr. hab. Krzysztof Buczyłko, Nikiel – niewidzialny wróg
13 Dr n. med. Aleksandra Wieczorek-Kawka, Pieluszkowe zapalenie skóry. Alergia czy podrażnienie?
14 Aleksandra Lipiec, Przewlekły wyprysk rąk – niedoceniany problem diagnostyczny i terapeutyczny
15 dr Barbara Bukowska, Bio-oszustwo: dlaczego biorezonans zawsze „coś” znajduje?
16 Agnieszka Stańczak, Plastry – ukryta przyczyna reakcji alergicznych
17 Natalia Łępa, Formaldehyd – toksyczny związek bliżej niż myślisz
18 Prof. dr hab. med. Marek Niedoszytko, Jak wygląda mastocytoza?

Prof. dr hab. n. med. Anna Zalewska-Janowska, Poza schematem, czyli różne oblicza atopowego zapalenia skóry

[1] Abdel-Mageed H.M., Atopic dermatitis: a comprehensive updated review of this intriguing disease with futuristic insights. Inflammopharmacology 2025;33:1161-87.

[2] Afshari M., Kolackova M., Rosecka M. et al., Unrevailing the skin; a comprehensive review of atopic dermatitis, current understanding, and approaches. Fron Immunol 2024;15:1361005.

[3] Jeskey J, Kurien C, Blunk H et al., Atopic dermatitis: a review of diagnosis and treatment. J Pediatr Pharmacol Ther 2024;29:587-603.

[4] Marko M, Pawliczak R., Błędy w rozpoznawaniu i leczeniu atopowego zapalenia skóry. Alergologa Polska 2024;11:61-8.

[5] Wilken B, Zaman M, Asai Y., Patient education in atopic dermatitis: a scoping review. Allergy, Asthma Clin Immunol 2023;19:89.

[6] Chai H., Siu W.S., Ma H. et al., Understanding atopic dermatitis: pathophysiology and management strategies. Biomolecules 2025;15:1500

[7] Nowicki R (red)., Atopowe zapalenie skóry w praktyce. Wyd. Cornetis, Wrocław 2013.

[8] Nowicki R., Trzeciak M., Kaczmarski M. et al., Atopic dermatitis. Interdisciplinary diagnostic and therapeutic recommendations of the Polish Dermatological Society, Polish Society of Allergology, Polish Pediatric Society and Polish Society of Family Medicine. Part I. Prophylaxis, topical treatemnet and phototherapy. Postepy Dermatol Alergol 2020;37:1-10.

[9] Flohr C., Mann J., New insights into the epidemiology of childhood atopic dermatitis. Allergy Eur J Allergy Clin Immunol 2014;69:3-16.

[10] Nutten S., Atopic dermatitis: global epidemiologyand risk factors. Ann Nutr Metab 2015;66:8-16.

[11] Courtney A., Su J.C., The psychology of atopic dermatitis J Clin Med. 2024;13:1602

[12] Kellog C., Smogorzewski J., Update on atopic dermatitis. Adv Pediatr 2023;70:157-70.

[13] Senra M.S., Wollenberg A., Psychodermatological aspets of atopic dermatitis. Br J Dermatol 2014;170 (Suppl. s1):38-43.

[14] Solomon I., Ilie M.A., Draghici C. et al., The impact of lifestyle factors on evolution of atopic dermatitis: an alternative approach (Review). Exp Ther Med. 2019;17:1078-84.

[15] Gruchała A., Galica K., Zalewska-Janowska A., Świąd w atopowym zapaleniu skóry. Dermatologia Praktyczna 2019;4:38-43.

[16] Filanovsky M.G., Pootongkam S., Tamburro J.E. et al., The financial and emotional impact of atopic dermatitis on children and their families. J Pediatr 2016;169:284-90.

Dr hab. n. med. Emilia Majsiak, W sieci zależności – AZS, alergia, molekuły

[1] Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345-360. https://doi.org/10.1016/S0140-6736(20)31286-1

[2] Czarnowicki T, He H, Krueger JG, Guttman-Yassky E. Atopic dermatitis endotypes and implications for targeted therapeutics. J Allergy Clin Immunol. 2019;143(1):1-11. https://doi.org/10.1016/j.jaci.2018.10.032

[3] Kiguchi T, Yamamoto-Hanada K, Saito-Abe M, Fukuie T, Ohya Y. Eczema phenotypes and IgE component sensitization in adolescents: A population-based birth cohort. Allergol Int. 2023;72(1):107-115. https://doi.org/10.1016/j.alit.2022.05.012

[4] Čelakovská J, Bukač J, Cermáková E, et al. Analysis of Results of Specific IgE in 100 Atopic Dermatitis Patients with the Use of Multiplex Examination ALEX2-Allergy Explorer. Int J Mol Sci. 2021;22(10):5286. https://doi.org/10.3390/ijms22105286

[5] Banerjee S, Resch Y, Chen KW, et al. Der p 11 Is a Major Allergen for House Dust Mite-Allergic Patients Suffering from Atopic Dermatitis. J Invest Dermatol. 2015;135(1):102-109. https://doi.org/10.1038/jid.2014.271

[6] Walsemann T, Böttger M, Traidl S, et al. Specific IgE against the house dust mite allergens Der p 5, 20 and 21 influences the phenotype and severity of atopic diseases. Allergy. 2023;78(3):731-742. https://doi.org/10.1111/all.15553

[7] Glatz M, Buchner M, von Bartenwerffer W, et al. Malassezia spp.-specific Immunoglobulin E Level is a Marker for Severity of Atopic Dermatitis in Adults. Acta Derm Venereol. 2015;95(2):191-196. https://doi.org/10.2340/00015555-1864

[8] Čelakovská J, Vaňková R, Bukač J, Cermáková E, Andrýs C, Krejsek J. Atopic Dermatitis and Sensitisation to Molecular Components of Alternaria, Cladosporium, Penicillium, Aspergillus, and Malassezia-Results of Allergy Explorer ALEX 2. J Fungi (Basel). 2021;7(3):183. https://doi.org/10.3390/jof7030183

[9] Vilhelmsson M, Glaser AG, Martinez DB, et al. Mutational analysis of amino acid residues involved in IgE-binding to the Malassezia sympodialis allergen Mala s 11. Mol Immunol. 2008;46(2):294-303. https://doi.org/10.1016/j.molimm.2008.07.036

[10] Schmid-Grendelmeier P, Flückiger S, Disch R, et al. IgE-mediated and T cell-mediated autoimmunity against manganese superoxide dismutase in atopic dermatitis. J Allergy Clin Immunol. 2005;115(5):1068-1075. https://doi.org/10.1016/j.jaci.2005.01.065

[11] Corzo Leon DE, Scheynius A, MacCallum DM, Munro CA. Malassezia sympodialis Mala s 1 allergen is a potential KELCH protein that cross reacts with human skin. FEMS Yeast Res. 2023;23:foad028. https://doi.org/10.1093/femsyr/foad028

[12] Scala E, Madonna S, Abeni D, et al. A microarray-based IgE-molecular mimicry index (IgE-MMI): A biomarker for disease severity, clinical phenotypes, and therapeutic response in atopic dermatitis? Allergy. 2024;79(12):3415-3429. https://doi.org/10.1111/all.16377

[13] Christensen MO, Barakji YA, Loft N, i wsp. Prevalence of and association between atopic dermatitis and food sensitivity, food allergy and challenge-proven food allergy: A systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2023;37(5):984-1003. https://doi.org/10.1111/jdv.18919

[14] Chu DK, Schneider L, Asiniwasis RN, et al. Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations. Ann Allergy Asthma Immunol. 2024;132(3):274-312. https://doi.org/10.1016/j.anai.2023.11.009

Dr n. med. Aleksandra Wieczorek-Kawka, Jak dbać o skórę atopową? Zasady pielęgnacji i błędy

[1] Frazier W., Bhardwaj N., Atopic dermatitis: diagnosis and treatment (2020). American Family Physician, 101(10), 590–598.

[2] Bylund S., Koyletzki L.B. et al., Prevalence and incidence of atopic dermatitis: A systematic review (2020). Acta Dermato-Venereologica, 100(12), adv00160.

[3] Sala-Cunill A., Lazaro M. et al., Basic Skin Care and Topical Therapies for Atopic Dermatitis: Essential Approaches and Beyond (2018). Journal of Investigational Allergology & Clinical Immunology, 28(6), 379–391.

[4] Nowicki R. J., Trzeciak M. et al., Atopowe zapalenie skóry. Interdyscyplinarne rekomendacje diagnostyczno-terapeutyczne Polskiego Towarzystwa Dermatologicznego, Polskiego Towarzystwa Alergologicznego, Polskiego Towarzystwa Pediatrycznego oraz Polskiego Towarzystwa Medycyny Rodzinnej. Część I. Profilaktyka, leczenie miejscowe i fototerapia (2019). Przegląd Dermatologiczny, 4(106), 354–371.

[5] Fluhr J.W., Muguet V. et al., Restoring skin hydration and barrier function: Mechanistic insights into basic emollients for xerosis cutis (2025). International Journal of Dermatology, 64(1), 5–12.

[6] McAleer M.A., Irvine A.D.: The multifunctional role of filaggrin in allergic skin disease (2013). Journal of Allergy and Clinical Immunology, 131(2), 280–291.

[7] Wilborn D., Amin R. et al., Skin Care in Neonates and Infants. A Scoping Review (2023). Skin Pharmacology and Physiology, (36), 51–66.

[8] Wollenberg A., Kinberger M. et al., European guideline (EuroGuiDerm) on atopic eczema – part II: Non-systemic treatments and treatment recommendations for special AE patient populations (2022). Journal of the European Academy of Dermatology and Venereology, 36(11), 1904–1926.

[9] Kottner J., Surber Ch., Skin care in nursing: A critical discussion of nursing practice and research (2016). International Journal of Nursing Studies, (61), 20–28.

[10] Majewski S., Bhattacharya T. et al., Sodium hypochlorite body wash in the management of Staphylococcus aureus–colonized moderate‐to‐severe atopic dermatitis in infants, children, and adolescents (2019). Pediatric Dermatology, 36(4), 442–447.

[11] Mactaggart E., Orchard D. et al., Baby wipes and nappy rash – what is the relationship? A review (2021). Australasian Journal of Dermatology, 62(4), 470–477.

[12] Ryczaj K., Dumycz K. et al., Contact allergens in moisturizers in preventative emollient therapy – A systematic review (2022). Clinical and Translational Allergy, 12(6), e12150.

[13] Ryczaj K., Chojnowska-Wójtowicz M. et al., Prevalence of major food allergens in skincare products for atopic dermatitis (2023). Postępy Dermatologii i Alergologii, 40(6), 762–765.

[14] Poljsak N., Kocevar Glavac N., Vegetable butters and oils as therapeutically and cosmetically active ingredients for dermal use: A review of clinical studies (2022). Frontiers in Pharmacology, 13, 868461.

[15] Guillet G., Guillet M.H., Percutaneous sensitization to almond oil in infancy and study of ointments in 27 children with food allergy (2000). Journal of Allergy and Clinical Immunology (Paris), 32(8), 309–311.

[16] Loden M., Andresson A.C. et al., Instrumental and dermatologist evaluation of the effect of glycerine and urea on dry skin in atopic dermatitis (2001). Skin Research and Technology, 7(4), 209–213.

Dr n. med. Katarzyna Poznańska-Kurowska, Jak skutecznie leczyć AZS? Przegląd dostępnych terapii

[1] Wollenberg A, et al. European Guideline (EuroGuiDerm) on atopic eczema: Living update. J Eur Acad Dermatol Venereol. 2025 May 2;39(9):1537–1566. doi: 1111/jdv.20639

[2] American Academy of Dermatology. Atopic dermatitis clinical guideline. https://www.aad.org/member/clinical-quality/guidelines/atopic-dermatitis

[3] Davis D et al. Focused update: Guidelines of care for the management of atopic dermatitis in adults. Journal of the American Academy of Dermatology, 2025; 93, 745.e1-745.e7

[4] European Medicines Agency. Dupixent (dupilumab) – EPAR / Product Information.

[5] European Medicines Agency. Ebglyss (lebrikizumab) – EPAR / Product Information.

[6] Narodowy Fundusz Zdrowia. Informacje dotyczące programów lekowych i realizacji świadczeń:

[7] Program lekowy B.124. Leczenie chorych z atopowym zapaleniem skóry (ICD-10: L20).

[8] Polskie Towarzystwo Chorób Atopowych. Mapa placówek – Program Lekowy B.124.

[9] Polskie Towarzystwo Chorób Atopowych. Poradnik dla pacjentów, opiekunów i lekarzy – Program Lekowy B.124.

[10] Drucker AM, Ellis AG, Bohdanowicz M et al. Systemic immunomodulatory treatments for patients with atopic dermatitis: a systematic review and network meta-analysis. JAMA Dermatol 2020; 156: 659–667.

[11] Mazur M. Najnowsze wytyczne leczenia AZS (2019). Wiadomości Dermatologiczne (Aktualizacja 27 sierpnia 2024)

[12] Paciorek-Milczarek P. Atopowe zapalenie skóry – jak diagnozować i leczyć w praktyce lekarza rodzinnego w 2025 r. w świetle aktualnych wytycznych. Lekarz POZ 3/2025

[13] Charakterystyki Produktów Leczniczych poszczególnych preparatów stosowanych w leczeniu AZS – aktualne wersje EMA/URPL.

Prof. dr. hab. n. med. Marta Chełmińska, Owady jadalne – jeść czy nie jeść? Oto jest pytanie!

[1] Palmer L.K., Marsh J.T., Lu M. et al., Shellfish Tropomyosin IgE Cross-Reactivity Differs Among Edible Insect Species (2020). Molecular Nutrition & Food Research, 64(8), e1900923.

[2] Wangorsch A., Jamin A., Spiric J. et al., Allergic Reaction to a Commercially Available Insect Snack Caused by House Cricket (Acheta domesticus) Tropomyosin (2024). Molecular Nutrition & Food Research, 68(5), e2300420.

[3] De Marchi L., Wangorsch A., Zoccatelli G., Allergens from Edible Insects: Cross-reactivity and Effects of Processing (2021). Current Allergy and Asthma Reports, 21(5), 35.

[4] Pali-Schöll I., Meinlschmidt P., Larenas-Linnemann D., Edible insects: Cross-recognition of IgE from crustacean- and house dust mite allergic patients, and reduction of allergenicity by food processing (2019). World Allergy Organization Journal, 12(1), 100006.

[5] Karnaneedi S., Johnston E.B., Bose U. et al., The Allergen Profile of Two Edible Insect Species-Acheta domesticus and Hermetia illucens (2024). Molecular Nutrition & Food Research, 68(16), e2300811.

[6] Jankowski W.M., Przychodniak D., Gormek W., Majsiak E., Kurowski M., Edible Insects as an Alternative Source of Nutrients: Benefits, Risks, and the Future of Entomophagy in Europe – A Narrative Review (2025). Foods, 14(2), 270.

[7] De Marchi L., Mainente F., Leonardi M. et al., Allergenicity assessment of the edible cricket Acheta domesticus in terms of thermal and gastrointestinal processing and IgE cross-reactivity with shrimp (2021). Food Chemistry, 359, 129878.

[8] Serological Cross-Reactivity and Potential Allergenic Risk of Edible Cricket Proteins in Children and Adolescents with House Dust Mite Allergy (2026). Journal of Agricultural and Food Chemistry, 74(11), 9735–9748.

Lek. Agnieszka Szczukocka, dr hab. n. med. Katarzyna Grzela

[1] Spolidoro GCI, Mustafa Ali M, Tesfaye Amera Y, et al. Prevalence estimates of eight big food allergies in Europe: updated systematic review and meta-analysis. Allergy. 2023;78(9):2361–2417. doi:10.1111/all.15801.

[2] Santos AF, Riggioni C, Agache I, et al. EAACI guidelines on the management of IgE-mediated food allergy. Allergy. 2025;80(1):14–36. doi:10.1111/all.16345.

[3] Jones SM, Kim EH, Nadeau KC, et al. Efficacy and safety of oral immunotherapy in children aged 1–3 years with peanut allergy: a randomised placebo-controlled study. Lancet. 2022;399(10322):359–371. doi:10.1016/S0140-6736(21)02390-4.

[4] Chinthrajah RS, Purington N, Andorf S, et al. Sustained outcomes in oral immunotherapy for peanut allergy: a randomised, double-blind, placebo-controlled, phase 2 study. Lancet. 2019;394(10207):1437–1449. doi:10.1016/S0140-6736(19)31793-3.

[5] Jones SM, Pons L, Roberts JL, et al. Clinical efficacy and immune regulation with peanut oral immunotherapy. J Allergy Clin Immunol. 2009;124(2):292–300.e1–97. doi:10.1016/j.jaci.2009.05.022.

[6] Varshney P, Jones SM, Scurlock AM, et al. A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response. J Allergy Clin Immunol. 2011;127(3):654–660. doi:10.1016/j.jaci.2010.12.1111.

[7] Anagnostou K, Islam S, King Y, et al. Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children: a phase 2 randomised controlled trial. Lancet. 2014;383(9925):1297–1304. doi:10.1016/S0140-6736(13)62301-6.

[8] PALISADE Group of Clinical Investigators. AR101 oral immunotherapy for peanut allergy. N Engl J Med. 2018;379(21):1991–2001. doi:10.1056/NEJMoa1812856.

[9] European Medicines Agency. Palforzia: cessation of marketing in the European Union. EMA/CHMP/38464/2025. 12 February 2026.

[10] Hunter H, Ue KL, Cornelius V, et al. Oral immunotherapy in peanut-allergic adults using real-world materials. Allergy. 2025;80(8):2310–2318. doi:10.1111/all.16493.

[11] Epstein-Rigbi N, Levy MB, Nachshon L, et al. Efficacy and safety of food allergy oral immunotherapy in adults. Allergy. 2023;78(3):803–811. doi:10.1111/all.15537.

[12] Santos AF, Riggioni C, Agache I, et al. EAACI guidelines on the diagnosis of IgE-mediated food allergy. Allergy. 2023;78(12):3057–3076. doi:10.1111/all.15902.

[13] Gawlik R. Kliniczne przeciwwskazania do immunoterapii alergenowej – bezwzględne i względne oraz stałe i czasowe. Alergologia Polska – Polish Journal of Allergology. 2018;5(4):180–185. doi:10.5114/pja.2018.80736.

[14] Pajno GB, Fernandez-Rivas M, Arasi S, et al. EAACI Guidelines on allergen immunotherapy: IgE-mediated food allergy. Allergy. 2018;73(4):799–815. doi:10.1111/all.13319.

[15] Łyżwa K, Chojnowska-Wójtowicz M, Zagórska W, Kulus M, Grzela K. Safety and clinical outcomes of high- versus low-dose oral peanut immunotherapy in Polish children with peanut allergy. Acta Paediatr. 2026. Published online August 5, 2026. doi:10.1111/apa.70704.

[16] Chu DK, Wood RA, French S, et al. Oral immunotherapy for peanut allergy: a systematic review and meta-analysis of efficacy and safety. Lancet. 2019;393(10187):2222–2232. doi:10.1016/S0140-6736(19)30420-9.

[17] Bird JA, Nilsson C, Brown K, Pham T, Tilles S, du Toit G, Assa’ad A. Long-term safety and immunologic outcomes of daily oral immunotherapy for peanut allergy. J Allergy Clin Immunol Glob. 2023;2(3):100120. doi:10.1016/j.jacig.2023.100120.

[18] Rossi CM, Terreehorst I, Apostolidou E, et al. A systematic review and meta-analysis on the induction of confirmed eosinophilic esophagitis as a side effect of allergen immunotherapy: an EAACI Task Force Report. Allergy. 2026;81(4):1024–1038. doi:10.1111/all.70183.

Diet. Marcelina Bartuzi-Lepczyńska, SIBO czy alergia pokarmowa? Podobne objawy, różne przyczyny

[1] Enck P. et al., Irritable bowel syndrome (2016). Nature Reviews. DiseasePrimers, 2, 1–24.

[2] Ghoshal U.C., Ghoshal U., Small intestinal bacterial overgrowth and otherintestinal disorders (2017). Gastroenterology Clinics, 46(1), 103–120.

[3] Pimentel M., Lembo A., Chey W.D. et al., Rifaximin therapy for patients withirritable bowel syndrome without constipation (2011). The New England Journal of Medicine, 364(1), 22–32.

[4] Sicherer S.H., Sampson H.A., Food allergy: A review and update onepidemiology, pathogenesis, diagnosis, prevention, and management (2018). The Journal of Allergy and Clinical Immunology: In Practice, 141(1), 41–58.

[5] Hills Jr, Ronald D. et al., Gut microbiome: profound implications for diet anddisease (2022). Kompass Nutrition & Dietetics, 2(1), 3–18.

[6] Bartuzi-Lepczynska M., Ukleja-Sokolowska N., Small intestine bacterialovergrowth in patients diagnosed with allergic disease: preliminary findings (2025). Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, 42(4),407–413.

[7] Quigley, Eamonn M.M., Joseph A.M., Pimentel M., AGA clinical practice updateon small intestinal bacterial overgrowth: expert review (2020). Gastroenterology,159(4), 1526–1532.

[8] Ukleja-Sokołowska N., Bartuzi M., The role of small intestinal bacterial overgrowth in food intolerances (2021). Alergoprofil, 17(2), 34–39.

[10] Yakoob J., Abbas Z., Khan R. et al., Small intestinal bacterial overgrowth andlactose intolerance contribute to irritable bowel syndrome symptomatology inPakistan (2011). Saudi Journal of Gastroenterology, 17(6), 371–375.

[11] Mareș R.C., Săsăran M.O., Mărginean C.O., Gut Microbiota and Food Allergy: AReview of Mechanisms and Microbiota-Targeted Interventions (2025). Nutrients,17(18), 3009.

[12] Marrs T., Jo J.-H., Perkin M.R. et al., Gut Microbiota Development duringInfancy: Impact of Introducing Allergenic Foods (2021). Journal of Allergy and ClinicalImmunology, 147, 613–621.

[13] Bartuzi-Lepczyńska M., Ukleja-Sokołowska N., Zespół rozrostu bakteryjnego jelita cienkiego – kontrowersje i zalecenia (2024). Alergia Astma Immunologia, 29(2).

Dr n. med. Kamil Janeczek, Poranny katar i kaszel u dziecka. Czy to alergia na roztocze?

[1] Majsiak E. Uwaga, roztocze atakują! Magazyn Strefa Alergii 2021; 1: 6-9. Online: https://strefaalergii.pl/molekuly/uwaga-roztocze-atakuja/

[2] Chen KW, Zieglmayer P, Zieglmayer R et al. Selection of house dust mite-allergic patients by molecular diagnosis may enhance success of specific immunotherapy. J Allergy Clin Immunol 2019; 143(3): 1248-1252.

[3] Solarz K, Pająk C. Risk of exposure of a selected rural population in South Poland to allergenic mites. Part I: indoor acarofauna of one-family houses. Exp Appl Acarol 2019; 77(3): 375-386.

[4] Rapiejko P, Jurkiewicz D. Przewlekły alergiczny nieżyt nosa. Alergoprofil 2014; 10(3): 3-11.

[5] Donath H, Klenner H, Hutter M et al. Severe bronchial hyperresponsiveness along with house dust mite allergy indicates persistence of asthma in young children. Pediatr Allergy Immunol 2023; 34(12): e14047.

[6] Walsemann T, Böttger M, Traidl S et al. Specific IgE against the house dust mite allergens Der p 5, 20 and 21 influences the phenotype and severity of atopic diseases. Allergy 2023; 78(3): 731-742.

[7] Safia A, Elhadi UA, Karam M et al. A meta-analysis of the prevalence and risk of mental health problems in allergic rhinitis patients. J Psychosom Res 2024; 184: 111813.

[8] Zhao Z, Zheng L, Huang X et al. Effects of mouth breathing on facial skeletal development in children: a systematic review and meta-analysis. BMC Oral Health 2021; 21(1): 108.

[9] Rozporządzenie Ministra Zdrowia z dnia 9 października 2023 r. zmieniające rozporządzenie w sprawie świadczeń gwarantowanych z zakresu podstawowej opieki zdrowotnej. Dziennik Ustaw, poz. 2226.

[10] Celi G, Brusca I, Scala E et al. House dust mite allergy in Italy-Diagnostic and clinical relevance of Der p 23 (and of minor allergens): A real-life, multicenter study. Allergy 2019; 74(9): 1787-1789.

[11] Wawrzeńczyk A, Bartuzi Z. Zespoły kliniczne alergii krzyżowej. Alergia Astma Immunologia 2018; 23 (2): 64-66.

[12] Błażowski Ł. Praktyczne aspekty prowadzenia immunoterapii podjęzykowej. Rekomendacje, zalecenia, praktyczne wskazówki. Alergia 2019; 4: 35-40.

[13] Kowal K. Podobieństwa i różnice alergenowej immunoterapii podskórnej i podjęzykowej. Alergia 2014; 4: 56-58.

[14] Nowe preparaty do immunoterapii z refundacją. Medycyna Praktyczna – Alergologia, 2025. Online: https://www.mp.pl/alergologia/aktualnosci/389520,nowe-preparaty-do-immunoterapii-na-liscie-refundacyjnej

[15] Samoliński B. Alergia na roztocze kurzu domowego. Diagnostyka i terapia. Alergia 2016; 3: 39-42.

Dr Barbara Bukowska, Niewidzialni współlokatorzy. Jak wygrać wojnę z roztoczami w sypialni?

[1] Jurkiewicz K., Jutel M., Smolinska S., Update on HDM Allergy: Principal Changes over the Years (2025). International Journal of Molecular Sciences, 26(12), 5660.

[2] Aggarwal P., Senthilkumaran S., Dust Mite Allergy (2023). StatPearls [Internet], Dostępne na: https://www.ncbi.nlm.nih.gov/books/NBK560718/

[3] Roztocze kurzu domowego, Medycyna Praktyczna, https://www.mp.pl/pacjent/alergie/chorobyalergiczne/alergeny/wziewne/62715,roztocze-kurzu-domowego, dostęp 19.08.2026 r.

[4] Arlian L.G., Platts-Mills T.A., The biology of dust mites and the remediation of mite allergens in allergic disease (2001). Journal of Allergy and Clinical Immunology, 107(3 Suppl), S406–S413.

[5] Demoly P., Matucci A., Rossi O., Vidal C., The disease burden in patients with respiratory allergies induced by house dust mites: a year-long observational survey in three European countries (2020). Clinical and Translational Allergy, 10, 27.

[6] InformedHealth.org, Overview: Dust mite allergies (2023). Institute for Quality and Efficiency in Health Care (IQWiG), Dostępne na: https://www.ncbi.nlm.nih.gov/books/NBK447098/

[7] Terreehorst I., Hak E., Oosting A.J. et al., Evaluation of impermeable covers for bedding in patients with allergic rhinitis (2003). The New England Journal of Medicine, 349(3), 237–246.

[8] Siebers R., Nam H.S., Crane J. Permeability of synthetic and feather pillows to live house dust mites and house dust (2004). Clinical & Experimental Allergy, 34(6), 888–90.

[9] Yu C.H., Yiin L.M., Tina Fan Z.H., Rhoads G.G., Evaluation of HEPA vacuum cleaning and dry steam cleaning in reducing levels of polycyclic aromatic hydrocarbons and house dust mite allergens in carpets (2009). Journal of Environmental Monitoring, 11(1), 205–211.

Aleksandra Lipiec, Ten grzyb jest niemal wszędzie. Cladosporium pod lupą

[1] Bensch K., Braun U., Groenewald J.Z., Crous P.W., The genus Cladosporium (2012). Studies in Mycology, 72, 1–401.

[2] Grzyby mikroskopowe. OBAS – Serwis Alergologiczny. Online: http://www.alergen.info.pl/Alergeny/Grzyby_mikroskopowe

[3] Durska G., Alergia na Cladosporium (2012). Medycyna Praktyczna. Online: https://www.mp.pl/pacjent/alergie/lista/71776,alergia-na-cladosporium

[4] Bogacka E., Alergia na grzyby pleśniowe: diagnostyka i leczenie (2008). Polski Merkuriusz Lekarski Medpress, XXIV, supl. 1, 11–14. Online: https://medpress.com.pl/pml/ePUBLI/T24S1/02.pdf

[5] Grinn-Gofroń A. i in., Zarodniki Cladosporium w powietrzu wybranych miast Polski w 2014 r. (2014). Alergoprofil, 10, 32–34.

[6] Xing H., Wang J., Sun Y., Wang H., Recent Advances in the Allergic Cross-Reactivity between Fungi and Foods (2022). Journal of Immunology Research, 1, 1–10. Online: https://onlinelibrary.wiley.com/doi/epdf/10.1155/2022/7583400

[7] Weryszko-Chmielewska E. i in., Health hazards related to conidia of Cladosporium – biological air pollutants in Poland, central Europe (2018). Journal of Environmental Sciences, 65, 271–281. Online: https://www.sciencedirect.com/science/article/abs/pii/S100107421630345X

[8] Rapiejko P. i in., Progowe stężenie pyłku roślin niezbędne do wywołania objawów alergicznych (2007). Otolaryngologia Polska, 61(4), 591–594. Online: https://www.sciencedirect.com/science/article/pii/S0030665707704912

[9] Wiszniewska M., Alergia dróg oddechowych na grzyby pleśniowe uwarunkowana ekspozycją komunalną i zawodową: występowanie, czynniki ryzyka, obraz kliniczny. Rozprawa na stopień doktora nauk medycznych (2007). Łódź.

[10] Popescu F.-D., Cross-reactivity between aeroallergens and food allergens. World Journal of Methodology, 5(2), 31–50. Online: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4482820/

[11] Ogórek R. i in., Characteristics and taxonomy of Cladosporium fungi (2012). Mikologia Lekarska, 19 (2), 80–85. Online: https://www.researchgate.net/publication/233818972_Characteristics_and_taxonomy_of_Cladosporium_fungi

[12] Breitenbach M., Crameri R., Lehrer S.B. (eds.), Fungal Allergy and Pathogenicity (2002). Chemical Immunology and Allergy, 81, 48–72.

Lek. Danuta Ostrowska-Reguła, Nie daj się zaskoczyć pyłkom. Kiedy zacząć brać leki na alergię?

[1] Fal A.M., Alergia, choroby alergiczne, astma. Medycyna Praktyczna, Kraków 2011 ISBN 978-83-7430-243-2.

[2] Majkowska-Wojciechowska B. Metody badań aerobiologicznych – postępy naukowe i technologiczne (2020). Alergia Astma Immunologia, 25(3), 141–153. Online: www.alergia-astma-immunologia.pl [stan na 20.12.2025].

[3] Kruszewski J.,Kowalski M., Kulus M.i in., Standardy w alergologii (2019). Wydawnictwo Medyczne Termedia, wydanie III, ISBN 978-83-7988-300-4.

[4] Rapiejko P., Czy coś nas zaskakuje w sezonie pylenia 2025, 05.09.2025. Lublin XXVI Konferencja Alergologów, Pulmonologów i Immunologów Klinicznych.

Prof. dr. hab. Krzysztof Buczyłko, Nikiel – niewidzialny wróg

[1] Bernstein J, Keller L. Pacheco K. Updates in Metal Allergy: A Review of New Pathways of Sensitization, Exposure, and Treatment. Curr Allergy Asthma Rep 25, 28 (2025). https://doi.org/10.1007/s11882-025-01209-6

[2] Śpiewak R. Alergia kontaktowa i alergiczny wyprysk kontaktowy .w: Alergia, choroby alergiczne, astma Tom II pod red. Andrzeja M. Fala, Medycyna Praktyczna 2011, Kraków. 370-391.

[3] Di Tola M, Marino M, Amodeo R, i wsp. Immunological characterization of the allergic contact mucositis related to the ingestion of nickel-rich foods. Immunobiology. 2014 Jul;219(7):522-30.

[4] Borghini R., Porpora MG, Casale R i wsp. Irritable Bowel Syndrome-Like Disorders in Endometriosis: Prevalence of Nickel Sensitivity and Effects of a Low-Nickel Diet. An Open-Label Pilot Study. Nutrients. 2020 Jan 28;12(2):341. doi: 10.3390/nu12020341

[5] Picarelli A, Greco N, Sciuttini F et al. High consumption of Nickel‐containing foods and IBS-like disorders: late events in a gluten-free diet. https://doi.org/10.1016/j. ecoenv.2021.112492 eacci

[6] Braga M, Quecchia C, Perotta C et al. Systemic nickel allergy syndrome: nosologic framework and usefulness of diet regimen for diagnosis. Int J Immunopathol Pharmacol. 2013;26(3):707-16.

[7] Kręcisz B, Chomiczewska D, Kieć-Świerczynska M et al. Systemic contact dermatitis to nickel present in cocoa in 14-year-old boy. Pediatr Dermatol. 2011;28(3):335-6

[8] Greco N, Pisano A, Mezzatesta L, Pettinelli M, Meacci A, Pignataro MG, Giordano C, Picarelli A. New Insights and Evidence on „Food Intolerances”: Non-Celiac Gluten Sensitivity and Nickel Allergic Contact Mucositis. Nutrients. 2023 May 17;15(10):2353. doi: 10.3390/nu15102353

[9] Di Gioacchino M, Ricciardi L, De Pità O et al. Nickel oral hyposensitization in patients with systemic nickel allergy syndrome. Ann Med. 2014 Feb;46(1):31-7.

Dr n. med. Aleksandra Wieczorek-Kawka, Pieluszkowe zapalenie skóry. Alergia czy podrażnienie?

[1] Chiriac A., Wollina U., Diaper dermatitis-a narrative review of clinical presentation, subtypes, and treatment (2024). Wiener Medizinische Wochenschrift, 174(11–12), 246–256.

[2] Kazakas E.L., Lane A.T., Diaper Dermatitis (2000). Pediatric Dermatology, 47(4), 909–919.

[3] Sarin A., Bhatia J. et al., Diaper Dermatitis – A Narrative Review. Asian Journal of Pediatric Dermatology 2023, 1(1), 19–23.

[4] Wollina U., The ABC of prevention and treatment of diaper dermatitis (2023). Cosmoderma, 3, 170.

[5] Kuchciak- Brancewicz M., Dermatologia okresu niemowlęcego. Choroby najczęstsze i wybrane (2021). Medipage, Warszawa, 86–92.

[6] Coelho M., Tan J-M. et al., Jacquet erosive dermatitis associated with commercial barrier cream (2024). Australasian Journal of Dermatoly, 65(3), e30–e33.

[7] Fortina A., Caroppo F. et l.., Allergic contact dermatitis in children (2020). Expert Review of Clinical Immunology, 16(6), 579–589.

[8] Novac-Bilić G., Vučić M. et al., Irritant and allergic contact dermatitis – skin lesion characteristic (2018). Acta Clinica Croatia, 57(4), 713–720.

[9] Alberta L., Sweeney S.M. et al., Diaper Dye Dermatitis (2025). Pediatrics, 116(3), e450–452.

[10] Wu Chang M., Nakrani R., Wipes (Baby Wipes) Six Children With Allergic Contact Dermatitis to Methylisothiazolinone in Wet (2014). Pediatrics, 133(2), e434–438.

[11] Piagatto P., Martelli A. et al., Contact dermatitis in children (2010). Italian Journal of Pediatrics, 36(2).

[12] Lemieux N., Irritant and Allergic Contact Dermatitis: Pediatric Primary Care Guide (2025). Topical Reviews in Pediatrics.

[13] Miklaszewska M., Wąsik F., Dermatologia pediatryczna, t. I. (2000). Volumed, Wrocław, 331–333.

Aleksandra Lipiec, Przewlekły wyprysk rąk – niedoceniany problem diagnostyczny i terapeutyczny

[1] Ghezzi G., Falcidia C., Paolino G. et al., Chronic Hand Eczema (CHE): A Narrative Review (2025). Dermatology and Therapy, 15(4), 771–795.

[2] Bissonnette R., Warren R.B., Pinter A. et al., Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials (2024). The Lancet, 404(10451), 461–473.

[3] Weisshaar E., Chronic Hand Eczema (2024). American Journal of Clinical Dermatology, 25(6), 909–926.

[4] Międzynarodowa Statystyczna Klasyfikacja Chorób i Problemów Zdrowotnych – ICD-10. Serwis Rzeczypospolitej Polskiej. Online: https://dane.gov.pl/pl/dataset/27/resource/55725,miedzynarodowa-statystyczna-klasyfikacja-chorob-i-problemow-zdrowotnych-icd-10/table

[5] Singh-Landa J., Bin Sawad A., Bappoo J. et al., Budget impact analysis of delgocitinib for moderate to severe Chronic Hand Eczema in the United States (2026). Journal of Medical Economics, 29(1), 1555–1564.

[6] English J., Aldridge R., Gawkrodger D. J. et al., Consensus statement on the management of chronic hand eczema (2009). Clinical and Experimental Dermatology, 34(7), 761–769.

[7] Decyzja wykonawcza komisji z dnia 19.9.2024 r. przyznająca na postawie rozporządzenia Parlamentu Europejskiego i Rady (WE) nr 726/2004 pozwolenie na dopuszczenie do obrotu produktu leczniczego stosowanego u ludzi „Anzupgo – delgocytynib” (2024).

[8] Janik J., FDA zatwierdza delgocitinib w leczeniu przewlekłego zapalenia skóry rąk (2025). Termedia. Online: https://www.termedia.pl/dermatologia/FDA-zatwierdza-delgocitinib-w-leczeniu-przewleklego-zapalenia-skory-rak,63334.html

[9] EMA/430975/2024. Anzupgo (delgocytynib). Przegląd wiedzy na temat leku Anzupgo i uzasadnienie udzielenia pozwolenia na dopuszczenie do obrotu w UE (2024).

[10] Anzupgo. Charakterystyka Produktu Leczniczego.

dr Barbara Bukowska, Bio-oszustwo: dlaczego biorezonans zawsze „coś” znajduje?

[1] Pokladnikova J., Park A.L., Draessler J., Lukacisinova A., Krcmova I., The use of complementary and alternative medicine by adults with allergies: a Czech national representative survey (2021). BMC Complementary Medicine and Therapies, 21(1), 171.

[2] Muresan D., Voidăzan S., Salcudean A., Bodo C.R., Grecu I,G., Bioresonance, an alternative therapy for mild and moderate depression (2022). Experimental and Therapeutic Medicine, 23(4), 264.

[3] Wüthrich B., Unproven techniques in allergy diagnosis (2005). Journal of Investigational Allergology and Clinical Immunology, 15(2), 86–90.

[4] Jutel M., Agache I., Zemelka-Wiacek M. et al., Nomenclature of allergic diseases and hypersensitivity reactions: Adapted to modern needs: An EAACI position paper (2023). Allergy, 78(11), 2851–2874.

[5] Kruszewski J., Metody niezweryfikowane i metody medycyny alternatywnej w leczeniu astmy i chorób alergicznych (1996). Alergia, Astma, Immunologia, 1(3), 172–183.

[6] Schöni M.H., Nikolaizik W.H., Schöni-Affolter F., Efficacy trial of bioresonance in children with atopic dermatitis (1997). International Archives of Allergy and Immunology, 112(3), 238–246.

[7] Lüdtke R., Kunz B., Seeber N., Ring J, Test-retest-reliability and validity of the Kinesiology muscle test (2001). Complementary Therapies in Medicine, 9(3), 141–145.

[8] Polskie Towarzystwo Alergologiczne, Zasady profilaktyki. Dostępne na: https://dlapacjentow.pta.med.pl/baza-wiedzy/zasady-profilaktyki/ (dostęp: 23.04.2026 r.).

[9] Bernstein I.L., Li J.T., Bernstein D.I. et al., Allergy diagnostic testing: an updated practice parameter (2008). Annals of Allergy, Asthma & Immunology, 100(3 Suppl 3), S1–148.

[10] Kelso J., Unproven Diagnostic Tests for Adverse Reactions to Foods (2018). The Journal of Allergy and Clinical Immunology: In Practice, 6(2), 362–365.

[11] Greiner A., Drexler H., Unnecessary Investigations in Environmental Medicine (2016). Deutsches Ärzteblatt International, 113(46), 773–780.

[12] Bousquet J., Khaltaev N., Cruz A.A. et al., Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen) (2008). Allergy, 63 Suppl 86, 8–160.

Agnieszka Stańczak, Plastry – ukryta przyczyna reakcji alergicznych

[1] Widman T.J., Oostman H., Storrs F.J., Allergic Contact Dermatitis from Medical Adhesive Bandages in Patients Who Report Having a Reaction to Medical Bandages (2008). Dermatitis, 19(1), 32–37.

[2] Khatsenko K., Khin Y., Maibach H., Allergic Contact Dermatitis to Components of Wearable Adhesive Health Devices (2020). Dermatitis, 31(5), 283–286.

[3] Mestach L., Huygens S., Goossens A., Gilissen L., Allergic contact dermatitis caused by acrylic-based medical dressings and adhesives (2018). Contact Dermatitis, 79(2), 81–84. Online: https://onlinelibrary.wiley.com/doi/10.1111/cod.13044

[4] Thornton N. J., Gibson B. R., Ferry A. M., Contact Dermatitis and Medical Adhesives: A Review (2021). Cureus 13(3), e14090. Online: https://www.cureus.com/articles/54891-contact-dermatitis-and-medical-adhesives-a-review#!/

[5] Atwater A. R. i in., Medical adhesive allergens: Retrospective analysis of cross-sectional data from the North American Contact Dermatitis Group, 2001-2018 (2022). Journal of the American Academy of Dermatology, 87(5), 1024–1032. Online: https://www.sciencedirect.com/science/article/pii/S0190962221029273?via%3Dihub

[6] Lipiec A., Kontaktowe zapalenie skóry – alergeny, objawy, metody leczenia (2024). Strefa Alergii. Online: https://strefaalergii.pl/choroby-alergiczne/alergia-kontaktowa/kontaktowe-zapalenie-skory-alergeny-objawy-metody-leczenia/

Natalia Łępa, Formaldehyd – toksyczny związek bliżej niż myślisz

[1] Noordiana N., Fatimah AB., Farhana YC., Formaldehyde content and quality characteristics of selected fish and seafood products (2011). International Food Research Journal, 18(1):125–131. Online: https://www.researchgate.net/publication/286157318_Formaldehyde_content_and_quality_characteristics_of_selected_fish_and_seafood_from_wet_markets

[2] Valverde-Santiago M., Pontel LB., Emerging mechanisms underlying formaldehyde toxicity and response (2025). Mol Cell, 5;85(11):2068-2079. Online:https://pubmed.ncbi.nlm.nih.gov/35878266/

[3] Herrero M., González N., Rovira J et al., Early-Life Exposure to Formaldehyde through Clothing (2022). Toxics, 30;10(7):361. Online: https://www.mdpi.com/1706170

[4] Pietrzyk Ł., Torres A., Denisow-Pietrzyk M., et al., Formaldehyde-related clinical symptoms reported by medical students during gross anatomy cadaver dissection (2016). Dermatology Review/Przegląd Dermatologiczny, 103(4):273–280. Online:https://www.termedia.pl/Formaldehyde-related-clinical-symptoms-reported-by-medical-students-during-gross-anatomy-cadaver-dissection,56,28148,1,1.html

[5] Goossens A., Aerts O., Contact allergy to and allergic contact dermatitis from formaldehyde and formaldehyde releasers: A clinical review and update (2022). Contact Dermatitis, 87(1): 20-27. Online:https://pubmed.ncbi.nlm.nih.gov/35229319/

[6] Latorre N., Silvestre JF., Monteagudo AF., Allergic Contact Dermatitis Caused by Formaldehyde and Formaldehyde Releasers (2011). Actas Dermo-Sifiliográficas (English Edition),102(2):86–97. Online:https://pubmed.ncbi.nlm.nih.gov/21338980/

[7] Mohamed Z.M. Salem., Böhm M., Srba J., Beránková J., Evaluation of formaldehyde emission from different types of wood-based panels and flooring materials using different standard test methods (2012). Building and Environment, 49:86-96. Online:https://doi.org/10.1016/j.buildenv.2011.09.011

[8] Zhu Y, Liang W., Effect of temperature and heat transfer on formaldehyde emissions from the medium density fiberboard: An experimental investigation (2025). Building and Environment, 283:113431. Online:https://www.sciencedirect.com/science/article/pii/S0360132325009060

[9] Rozporządzenie Komisji (UE) 2023/1464 z dnia 14 lipca 2023 r. zmieniające załącznik XVII do rozporządzenia (WE) nr 1907/2006 Parlamentu Europejskiego i Rady w odniesieniu do formaldehydu i substancji uwalniających formaldehyd. Dz. Urz. UE L 180 z 17.07.2023, s. 12–20. Online:https://sip.lex.pl/akty-prawne/dzienniki-UE/rozporzadzenie-2023-1464-zmieniajace-zalacznik-xvii-do-rozporzadzenia-we-nr-72186518

[10] González-Muñoz P., Conde-Salazar L., Vañó-Galván S., Allergic Contact Dermatitis Caused by Cosmetic Products (2014). Actas Dermosifiliogr, 105:822-32

[11] Valdes F., McNamara S., Keri J., Allergic Contact Dermatitis From Transient Formaldehyde Exposure in a Traveler: Are All Backpacks Created Equal? (2020). Cureus, 12(12):e12252. Online:https://pubmed.ncbi.nlm.nih.gov/33505817/

[12] Kiracofe EA., Zirwas MJ., Formaldehyde in textiles–what dermatologists need to know about the relationship to contact dermatitis: a review of the US Government Accountability Office’s Report to Congressional Committees (2012). J Am Acad Dermatol, 67(2):313-4. Online:https://pubmed.ncbi.nlm.nih.gov/22794805/

[13] Kaden DA., Mandin C., Nielsen GD., et al., Formaldehyde. In: WHO Guidelines for Indoor Air Quality: Selected Pollutants (2010). Geneva: World Health Organization, 3. Online:https://www.ncbi.nlm.nih.gov/books/NBK138711/

Prof. dr hab. med. Marek Niedoszytko, Jak wygląda mastocytoza?

[1] Niedoszytko M, Gorska A, Brockow K et al.: Prevalence of hypersensitivity reactions in various forms of mastocytosis: A pilot study of 2485 adult patients with mastocytosis collected in the ECNM registry. Allergy. 2024 Sep;79(9):2470-2481. doi: 10.1111/all.16132. Epub 2024 Apr 23. PMID: 38651829.

[2] Hans-Peter H., Sotlar K., Metzgeroth G., Reiter A., Valent P., Mastocytosis and the Updated WHO Classification (2016, 2017): What is Really New? (2018). Annals of Hematology & Oncology, 5(2), 1194.

[3] Valent P., Akin C., Hartmann K. et al., Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future (2017). Cancer Research, 77(6), 261–1270.

[4] Harmonization of Diagnostic Criteria in Mastocytosis for Use in Clinical Practice: WHO vs ICC vs AIM/ECNM (2024). The Journal of Allergy and Clinical Immunology: In Practice, 12(12), 3250–3260, e5.

[5] Mital A., Niedoszytko M., Hellmann A., Ochrem B., Mastocytoza (2024). Interna Szczeklika. Podręcznik chorób wewnętrznych. Kraków, Medycyna Praktyczna.

[6] Valent P., Hartmann K., Schwaab J. et al., Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User’s Guide for Daily Clinical Practice (2022). Review and Feature Article, 10(8), 1999–2012.

[7] Valent P., Akin C., Hartmann K. et al., Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal (2021). Hemasphere, 5(11), e646.

[8] Pardanani A., Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management (2023). American Journal of Hematology, 98(7), 1097–1116.

[9] Spolak-Bobryk N., Romantowski J., Kujawska-Danecka H., Niedoszytko M., Mastocytosis patients’ cognitive dysfunctions correlate with the presence of spindle‐shaped mast cells in bone marrow (2022). Clinical and Translational Allergy, 12(1), e12093.

[10] Vos B.J.P.R., van Anrooij B., van Doormaal J.J., Dubois A.E.J, Oude Elberink J.N.G., Fatal Anaphylaxis to Yellow Jacket Stings in Mastocytosis: Options for Identification and Treatment of At-Risk Patients (2017). The Journal of Allergy and Clinical Immunology: In Practice, 5(5), 1264–1271.

[11] Blank S., Grosch J., Ollert M., Bilò M.B., Precision Medicine in Hymenoptera Venom Allergy: Diagnostics, Biomarkers, and Therapy of Different Endotypes and Phenotypes (2020). Frontiers in Immunology, 11, 579409.

[12] Bonadonna P., Zanotti R., Pagani M. et al., Anaphylactic Reactions After Discontinuation of Hymenoptera Venom Immunotherapy: A Clonal Mast Cell Disorder Should Be Suspected (2018). The Journal of Allergy and Clinical Immunology: In Practice, 6(4), 1368–1372.

[13] Craig J.W., Hasserjian R.P, Kim A.S. et al., Detection of the KITD816V mutation in myelodysplastic and/or myeloproliferative neoplasms and acute myeloid leukemia with myelodysplasia-related changes predicts concurrent systemic mastocytosis (2020). Modern Pathology, 33(6), 1135–1145.

[14] Valent P., Akin C., Bonadonna P. et al., Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome (2019). The Journal of Allergy and Clinical Immunology: In Practice, 7(4), 1125–1133.

[15] Lyons J.J., Hereditary Alpha Tryptasemia: Genotyping and Associated Clinical Features (2018). Immunology and Allergy Clinics of North America, 38(3), 483–495.

[16] Sprinzl B., Greiner G., Uyanik G. et al., Genetic Regulation of Tryptase Production and Clinical Impact: Hereditary Alpha Tryptasemia, Mastocytosis and Beyond (2021). International Journal of Molecular Sciences, 22(5), 2458.

[17] Bojahr K., Dylczyk-Sommer A., Biedrzycka A. i in., Przygotowanie chorych na mastocytozę, zespół aktywacji mastocytów do zabiegu chirurgicznego, porodu oraz badań radiologicznych (2023). Alergologia Polska – Polish Journal of Allergology, 10(4), 301–309.